Gold Daniel Allen's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Feb 13, 2026
- Accession no.
- 0001193125-26-052128
- Filed
- Feb 13, 2026
- Trade date
- Feb 11-13, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $32.7M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gold Daniel AllenCIK 0001832142 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | Common Shares | SSaleDisposed | −425,000 | $26.67 | −$11,334,750 | 15,928,113 | Indirect | Duplicate filing |
| Feb 12, 2026 | Common Shares | SSaleDisposed | −150,000 | $26.72 | −$4,008,000 | 15,778,113 | Indirect | Duplicate filing |
| Feb 12, 2026 | Common Shares | SSaleDisposed | −275,000 | $26.76 | −$7,359,000 | 15,503,113 | Indirect | Duplicate filing |
| Feb 13, 2026 | Common Shares | SSaleDisposed | −150,784 | $26.49 | −$3,994,268.16 | 15,352,329 | Indirect | Duplicate filing |
| Feb 13, 2026 | Common Shares | SSaleDisposed | −225,000 | $26.50 | −$5,962,500 | 15,127,329 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.